Pharmacokinetics and Bioavailability of New Synthetic 5-HT2C Agonists, KKHQ80109 and KKHQ80114, in Sprague-Dawley Rats

Authors
Hye-Yeon ImHyun-Ah ChooAe Nim PaeOh-Seung Kwon
Issue Date
2009-10
Publisher
한국약제학회
Citation
Journal of Pharmaceutical Investigation, v.39, no.5, pp.327 - 331
Abstract
5-HT2C receptors have been considered as therapeutic targets for the treatment of various central nervous system disorders such as depression, anxiety, epilepsy, schizophrenia, and sleep disorders. We chemically synthesized KKHQ80109 (K09) and KKHQ80114 (K14), selective 5-HT2C agonists, with the purpose of developing therapeutic agents for the treatment of obesity. The objective of this work is to investigate pharmacokinetic parameters and bioavailability of K09 and K14 in rats given orally or intravenously. Oral administration of 20 mg/kg K09 results in 4.11 hr of the terminal half-life and 89.16 ng/ml of Cmax at 5.00 hr (Tmax). The terminal half-life of K14 was 3.83 hr with 215.81 ng/ml of Cmax at 3.33 hr (Tmax) after oral dosing of 20 mg/kg K14, indicating that K14 is more rapidly absorbed than K09. Bioavailability showed 0.17-0.21 for K09 and 0.19-0.23 for K14. Urinary excretion of parent K09 and K14 was less than 1%, indicating that K09 and K14 undergo very extensive hepatic metabolism.
Keywords
Rats; 5-HT2C agonists; KKHQ80109; KKHQ80114; Pharmacokinetics; Bioavailability
ISSN
2093-5552
URI
https://pubs.kist.re.kr/handle/201004/132060
Appears in Collections:
KIST Article > 2009
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE